Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 406


A Subset of Cancer-Associated Fibroblasts Determines Therapy Resistance.

Huelsken J, Hanahan D.

Cell. 2018 Feb 8;172(4):643-644. doi: 10.1016/j.cell.2018.01.028.


Swiss Medical Weekly congratulates Jaco van Rheenen, recipient of the Dr Josef Steiner Cancer Research Foundation Award for 2017.

Hanahan D.

Swiss Med Wkly. 2017 Nov 9;147:w14542. doi: 10.4414/smw.2017.14542. eCollection 2017 Nov 9. No abstract available.


Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.

Fankhauser M, Broggi MAS, Potin L, Bordry N, Jeanbart L, Lund AW, Da Costa E, Hauert S, Rincon-Restrepo M, Tremblay C, Cabello E, Homicsko K, Michielin O, Hanahan D, Speiser DE, Swartz MA.

Sci Transl Med. 2017 Sep 13;9(407). pii: eaal4712. doi: 10.1126/scitranslmed.aal4712.


Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G.

Sci Transl Med. 2017 Apr 12;9(385). pii: eaak9679. doi: 10.1126/scitranslmed.aak9679.


Procathepsin E is highly abundant but minimally active in pancreatic ductal adenocarcinoma tumors.

O'Donoghue AJ, Ivry SL, Chaudhury C, Hostetter DR, Hanahan D, Craik CS.

Biol Chem. 2016 Sep 1;397(9):871-81. doi: 10.1515/hsz-2016-0138.


Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.

Allen E, Miéville P, Warren CM, Saghafinia S, Li L, Peng MW, Hanahan D.

Cell Rep. 2016 May 10;15(6):1144-60. doi: 10.1016/j.celrep.2016.04.029. Epub 2016 Apr 28.


Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM.

Cancer Discov. 2016 Mar;6(3):270-85. doi: 10.1158/2159-8290.CD-15-0827. Epub 2015 Dec 29. Erratum in: Cancer Discov. 2016 Jul;6(7):802.


The consensus molecular subtypes of colorectal cancer.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S.

Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.


A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.

Sadanandam A, Wullschleger S, Lyssiotis CA, Grötzinger C, Barbi S, Bersani S, Körner J, Wafy I, Mafficini A, Lawlor RT, Simbolo M, Asara JM, Bläker H, Cantley LC, Wiedenmann B, Scarpa A, Hanahan D.

Cancer Discov. 2015 Dec;5(12):1296-313. doi: 10.1158/2159-8290.CD-15-0068. Epub 2015 Oct 7.


Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit.

Shchors K, Massaras A, Hanahan D.

Cancer Cell. 2015 Oct 12;28(4):456-471. doi: 10.1016/j.ccell.2015.08.012. Epub 2015 Sep 24.


Deficiency for the cysteine protease cathepsin L impairs Myc-induced tumorigenesis in a mouse model of pancreatic neuroendocrine cancer.

Brindle NR, Joyce JA, Rostker F, Lawlor ER, Swigart-Brown L, Evan G, Hanahan D, Shchors K.

PLoS One. 2015 Apr 30;10(4):e0120348. doi: 10.1371/journal.pone.0120348. eCollection 2015.


Reply to Colorectal cancer classification based on gene expression is not associated with FOLFIRI response.

Sadanandam A, Gray J, Hanahan D.

Nat Med. 2014 Nov;20(11):1231-2. doi: 10.1038/nm.3742. No abstract available.


Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications.

Sadanandam A, Wang X, de Sousa E Melo F, Gray JW, Vermeulen L, Hanahan D, Medema JP.

Cell Cycle. 2014;13(3):353-7. doi: 10.4161/cc.27769. Epub 2014 Jan 9.


Rethinking the war on cancer.

Hanahan D.

Lancet. 2014 Feb 8;383(9916):558-63. doi: 10.1016/S0140-6736(13)62226-6. Epub 2013 Dec 16. Review.


A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy.

De Palma M, Coukos G, Hanahan D.

Cancer Cell. 2013 Nov 11;24(5):559-61. doi: 10.1016/j.ccr.2013.10.019.


Bioavailable copper modulates oxidative phosphorylation and growth of tumors.

Ishida S, Andreux P, Poitry-Yamate C, Auwerx J, Hanahan D.

Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19507-12. doi: 10.1073/pnas.1318431110. Epub 2013 Nov 11.


Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase.

Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lønborg A, Vindeløv SD, Hanahan D, Arenz C, Ejsing CS, Kirkegaard T, Rohde M, Nylandsted J, Jäättelä M.

Cancer Cell. 2013 Sep 9;24(3):379-93. doi: 10.1016/j.ccr.2013.08.003.


Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection.

Keliher EJ, Reiner T, Earley S, Klubnick J, Tassa C, Lee AJ, Ramaswamy S, Bardeesy N, Hanahan D, Depinho RA, Castro CM, Weissleder R.

Neoplasia. 2013 Jul;15(7):684-93.


Identification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis.

Hunter KE, Quick ML, Sadanandam A, Hanahan D, Joyce JA.

PLoS One. 2013 May 14;8(5):e64472. doi: 10.1371/journal.pone.0064472. Print 2013.


A colorectal cancer classification system that associates cellular phenotype and responses to therapy.

Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D.

Nat Med. 2013 May;19(5):619-25. doi: 10.1038/nm.3175. Epub 2013 Apr 14.


Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.

Shchors K, Persson AI, Rostker F, Tihan T, Lyubynska N, Li N, Swigart LB, Berger MS, Hanahan D, Weiss WA, Evan GI.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):E1480-9. doi: 10.1073/pnas.1219142110. Epub 2013 Mar 29.


Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion.

Li L, Hanahan D.

Cell. 2013 Mar 28;153(1):86-100. doi: 10.1016/j.cell.2013.02.051.


A biocompatible in vivo ligation reaction and its application for noninvasive bioluminescent imaging of protease activity in living mice.

Godinat A, Park HM, Miller SC, Cheng K, Hanahan D, Sanman LE, Bogyo M, Yu A, Nikitin GF, Stahl A, Dubikovskaya EA.

ACS Chem Biol. 2013 May 17;8(5):987-99. doi: 10.1021/cb3007314. Epub 2013 Mar 29.


Accessories to the crime: functions of cells recruited to the tumor microenvironment.

Hanahan D, Coussens LM.

Cancer Cell. 2012 Mar 20;21(3):309-22. doi: 10.1016/j.ccr.2012.02.022. Review.


Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis.

Shchors K, Nozawa H, Xu J, Rostker F, Swigart-Brown L, Evan G, Hanahan D.

Oncogene. 2013 Jan 24;32(4):502-13. doi: 10.1038/onc.2012.60. Epub 2012 Mar 5.


The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities.

De Palma M, Hanahan D.

Mol Oncol. 2012 Apr;6(2):111-27. doi: 10.1016/j.molonc.2012.01.011. Epub 2012 Feb 4. Review.


Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.

Olson P, Chu GC, Perry SR, Nolan-Stevaux O, Hanahan D.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):E1275-84. doi: 10.1073/pnas.1111079108. Epub 2011 Nov 14.


A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.

Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, Batteux F, Sandoval F, Adotevi O, Chiu C, Garcia S, Tanchot C, Lone YC, Ferreira LC, Nelson BH, Hanahan D, Fridman WH, Johannes L, Tartour E.

Blood. 2011 Nov 3;118(18):4853-62. doi: 10.1182/blood-2011-01-329656. Epub 2011 Sep 9.


Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression.

Franco M, Roswall P, Cortez E, Hanahan D, Pietras K.

Blood. 2011 Sep 8;118(10):2906-17. doi: 10.1182/blood-2011-01-331694. Epub 2011 Jul 21.


Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B.

Falcon BL, Pietras K, Chou J, Chen D, Sennino B, Hanahan D, McDonald DM.

Am J Pathol. 2011 Jun;178(6):2920-30. doi: 10.1016/j.ajpath.2011.02.019.


Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner.

Xie L, Duncan MB, Pahler J, Sugimoto H, Martino M, Lively J, Mundel T, Soubasakos M, Rubin K, Takeda T, Inoue M, Lawler J, Hynes RO, Hanahan D, Kalluri R.

Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9939-44. doi: 10.1073/pnas.1105041108. Epub 2011 May 27.


Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.

Allen E, Walters IB, Hanahan D.

Clin Cancer Res. 2011 Aug 15;17(16):5299-310. doi: 10.1158/1078-0432.CCR-10-2847. Epub 2011 May 27.


Endogenous Myc maintains the tumor microenvironment.

Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L.

Genes Dev. 2011 May 1;25(9):907-16. doi: 10.1101/gad.2038411. Epub 2011 Apr 8.


Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.

Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW.

Nat Med. 2011 Apr;17(4):500-3. doi: 10.1038/nm.2344. Epub 2011 Apr 3.


Translational medicine: Cancer lessons from mice to humans.

Tuveson D, Hanahan D.

Nature. 2011 Mar 17;471(7338):316-7. doi: 10.1038/471316a. No abstract available.


Hallmarks of cancer: the next generation.

Hanahan D, Weinberg RA.

Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013. Review.


Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes.

Nolan-Stevaux O, Truitt MC, Pahler JC, Olson P, Guinto C, Lee DC, Hanahan D.

Genes Cancer. 2010 Feb;1(2):125-41. doi: 10.1177/1947601909358722.


Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis.

Chun MG, Mao JH, Chiu CW, Balmain A, Hanahan D.

Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17268-73. doi: 10.1073/pnas.1012705107. Epub 2010 Sep 20.


Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

Ishida S, McCormick F, Smith-McCune K, Hanahan D.

Cancer Cell. 2010 Jun 15;17(6):574-83. doi: 10.1016/j.ccr.2010.04.011.


Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.

Ulanet DB, Ludwig DL, Kahn CR, Hanahan D.

Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10791-8. doi: 10.1073/pnas.0914076107. Epub 2010 May 10.


Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.

Erez N, Truitt M, Olson P, Arron ST, Hanahan D.

Cancer Cell. 2010 Feb 17;17(2):135-47. doi: 10.1016/j.ccr.2009.12.041. Epub 2010 Feb 4. Erratum in: Cancer Cell. 2010 May 18;17(5):523. Arron, Sarah Tuttleton [added].


Tissue-penetrating delivery of compounds and nanoparticles into tumors.

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E.

Cancer Cell. 2009 Dec 8;16(6):510-20. doi: 10.1016/j.ccr.2009.10.013.


MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.

Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D.

Genes Dev. 2009 Sep 15;23(18):2152-65. doi: 10.1101/gad.1820109.


Cancer. Breaching the cancer fortress.

Olson P, Hanahan D.

Science. 2009 Jun 12;324(5933):1400-1. doi: 10.1126/science.1175940. No abstract available.


Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O.

Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027.


Genetic ablation of Bcl-x attenuates invasiveness without affecting apoptosis or tumor growth in a mouse model of pancreatic neuroendocrine cancer.

Hager JH, Ulanet DB, Hennighausen L, Hanahan D.

PLoS One. 2009;4(2):e4455. doi: 10.1371/journal.pone.0004455. Epub 2009 Feb 11.


GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation.

Nolan-Stevaux O, Lau J, Truitt ML, Chu GC, Hebrok M, Fernández-Zapico ME, Hanahan D.

Genes Dev. 2009 Jan 1;23(1):24-36. doi: 10.1101/gad.1753809.

Supplemental Content

Loading ...
Support Center